The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression. (13th November 2017)

• Record Type: Journal Article
• Authors: Filosso, Pier Luigi; Kidd, Mark; Roffinella, Matteo; Lewczuk, Anna; Chung, Kyung-Min; Kolasinska-Cwikla, Agnieszka; Cwikla, Jaroslaw; Lowczak, Anna; Doboszynska, Anna; Malczewska, Anna; Catalano, Maria; Zunino, Valentina; Boita, Monica; Arvat, Emanuela; Cristofori, Riccardo; Guerrera, Francesco; Oliaro, Alberto; Tesselaar, Margot; Buikhuisen, Wieneke; Kos-Kudla, Beata; Papotti, Mauro; Bodei, Lisa; Drozdov, Ignat; Modlin, Irvin
• Is Part Of: European journal of cardio-thoracic surgery. Volume 53:Number 3(2018)
• Page Start: 631
• Page End: 639
• Publication Date: 2017-11-13
• Subjects: Bronchopulmonary neuroendocrine tumours -- Carcinoid -- Neuroendocrine tumour multigene blood test -- Lung surgery -- Thoracic; Heart -- Surgery -- Periodicals; Chest -- Surgery -- Periodicals; 617.54
• DOI: 10.1093/ejcts/ezx386
• Languages: English
• ISSNs: 1010-7940

Abstract

Abstract: OBJECTIVES: The management of bronchopulmonary neuroendocrine tumours (BPNETs) is difficult, since imaging, histology and biomarkers have a limited value in diagnosis, predicting outcome and defining therapeutic efficacy. We evaluated a NET multigene blood test (NETest) to diagnose BPNETs, assess disease status and evaluate surgical resection. METHODS: (i) Diagnostic cohort: BP carcinoids ( n = 118)—typical carcinoid, n = 67 and atypical carcinoid, n = 51; other lung NEN (large-cell neuroendocrine carcinoma and small-cell lung carcinoma, n = 13); adenocarcinoma, ( n = 26); squamous cell carcinoma ( n = 23); controls ( n = 90) and chronic obstructive pulmonary disease ( n = 18). (ii) Surgical cohort, n = 28: BP carcinoids ( n = 16: typical carcinoid 12; atypical carcinoid 4); large-cell neuroendocrine carcinoma, n = 3; lung adenocarcinoma, n = 8 and squamous cell carcinoma, n = 1. Blood sampling was performed presurgery and 30 days post-surgery. Transcript levels measured by quantitative polymerase chain reaction were calculated as activity scores (0–100% scale: normal < 14%) and compared with chromogranin A (enzyme-linked immunosorbent assay; normal <109 ng/ml). RESULTS: NETest was significantly elevated in carcinoids (48.7 ± 27%) versus controls (6 ± 6%, P < 0.001) with metrics: sensitivity 93%, specificity 89%, positive predictive value 92% and negative predictive value 91%. NETest differentiated progressive disease (73 ± 22%) from stable disease (36 ± 19%, P < 0.001) and R0 resections (10 ± 5%, P < 0.001, area under the curve: 0.98). Levels in chronic obstructive pulmonary disease and lung cancers were 18–24% while elevated in small-cell lung carcinoma/large-cell neuroendocrine carcinoma (59 ± 10%). In BPNETs on postoperative Day 30, NETest decreased by 60% ( P < 0.001). Chromogranin A was elevated in only 40% of carcinoids and not altered by surgery. CONCLUSIONS: Blood NET gene levels accurately identified BPNETs (100%) and differentiated these from controls, benign and malignant lung disease. Progressive disease could be identified and surgical resection verified. Chromogranin A had no clinical utility. Monitoring NET transcript levels in blood will facilitate management by detecting residual tumour and identifying progressive disease.